Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by longterm56on Aug 01, 2019 8:43pm

120 Views

Post# 29986982

RE:Lots of encouraging info

Really? You call this encouraging???

While [adding ibalizumab to optimized background ART] is not cost-effective, the small number of eligible patients makes the budget impact of adding ibalizumab to OBR relatively small in the US.”

- LT

SPCEO1 wrote: https://www.infectiousdiseaseadvisor.com/home/topics/hiv-aids/novel-monoclonal-antibody-infection-for-tx-of-hiv-effective-for-pts-with-mdr-infection/

Bullboard Posts

3 Mid-Sized Stocks to Consider This Season